APA (7th ed.) Citation

Joffe, E., Kumar, A., Tuscano, J. M., Moskowitz, A. J., Owens, C., Noy, A., . . . Vardhana, S. (2026). Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial. Cancers, 18(2), 284. https://doi.org/10.3390/cancers18020284

Chicago Style (17th ed.) Citation

Joffe, Erel, et al. "Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial." Cancers 18, no. 2 (2026): 284. https://doi.org/10.3390/cancers18020284.

MLA (9th ed.) Citation

Joffe, Erel, et al. "Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial." Cancers, vol. 18, no. 2, 2026, p. 284, https://doi.org/10.3390/cancers18020284.